螺内酯治疗中心性浆液性脉络膜视网膜病变：一个激发-再激发病例
Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case.
作者信息
Ryan Edwin H, Pulido Christine M
机构信息
VitreoRetinal Surgery, PA, Edina, Minnesota.
出版信息
Retin Cases Brief Rep. 2015 Summer;9(3):235-8. doi: 10.1097/ICB.0000000000000147.
PURPOSE
To present a case of central serous chorioretinopathy (CSC) treatment with spironolactone in a challenge-rechallenge pattern.
METHODS
At presentation, fundus photography, fluorescein angiography, spectral domain optical coherence tomography, and enhanced depth imaging ocular coherence tomography were performed in both eyes. The patient was prescribed 25 mg spironolactone daily along with serum potassium monitoring. At follow-ups, spectral domain optical coherence tomography and enhanced depth imaging ocular coherence tomography were performed.
RESULTS
A 37-year-old white male accountant presenting with CSC. Spironolactone treatment resolved the CSC. After the patient discontinued treatment, it returned. After returning to daily treatment, the CSC again resolved.
CONCLUSION
Spironolactone was an effective treatment of CSC in this case. Other groups have reported similar findings with eplerenone, a similar drug.
目的
介绍一例采用螺内酯以激发-再激发模式治疗中心性浆液性脉络膜视网膜病变（CSC）的病例。
方法
初诊时，对双眼进行了眼底照相、荧光素血管造影、光谱域光学相干断层扫描和增强深度成像光学相干断层扫描。患者每日服用25毫克螺内酯，并监测血清钾。随访时，进行了光谱域光学相干断层扫描和增强深度成像光学相干断层扫描。
结果
一名37岁的白人男性会计师患有CSC。螺内酯治疗使CSC得到缓解。患者停药后，病情复发。恢复每日治疗后，CSC再次缓解。
结论
在该病例中，螺内酯是治疗CSC的有效药物。其他研究组报道了使用依普利酮（一种类似药物）时的类似发现。
Zotero 插件